Erratum: DTuberculosis (The Lancet (2016) 387(10024) (1211–1226) (S0140673615001518) (10.1016/S0140-6736(15)00151-8));Tuberculosis

The Lancet

Volumn 387, Issue 10024, 2016, Pages 1211-1226

  Dheda, Keertan ^a,c   Barry, Clifton E ^b,c   Maartens, Gary ^b,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CORTICOSTEROID; TUBERCULOSTATIC AGENT; GLUCOCORTICOID;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONTACT EXAMINATION; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE TRANSMISSION; DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; INCIDENCE; INFECTION CONTROL; INFECTION RISK; LATENT TUBERCULOSIS; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; SHORT COURSE THERAPY; TUBERCULOSIS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; TRANSMISSION; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; GLUCOCORTICOIDS; HUMANS; PROGNOSIS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84961214191     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00399-2     Document Type: Erratum

References (159)

1. I Comas, M Coscolla, T Luo et al. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans Nat Genet 45 2013 1176 1182
2. EW Tiemersma, MJ van der Werf, MW Borgdorff, BG Williams, NJ Nagelkerke Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review PLoS One 6 2011 e17601
3. F Ryan The Forgotten Plague: how the battle against tuberculosis was won - and lost 1994 Back Bay Books Boston, MA
4. T Cohen, C Dye Epidemiology PDO Davies SB Gordon G Davies Clinical tuberculosis 5th edn. 2014 CRC Press Florida, USA 19 36
5. Global tuberculosis Report WHO 2014 World Health Organization Geneva, Switzerland
6. K Dheda, T Gumbo, NR Gandhi et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis Lancet Respir Med 2 2014 321 338
7. E Pietersen, E Ignatius, EM Streicher et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study Lancet 383 2014 1230 1239
8. E Berti, L Galli, E Venturini, M de Martini, E Chiappini Tuberculosis in childhood: a systematic review of national and international guidelines BMC Infect Dis 14 suppl 1 2014 S3
9. CM Perez-Velez, BJ Marais Tuberculosis in children N Engl J Med 367 2012 348 361
10. M Pai, D Menzies Interferon-gamma release assays for diagnosis of latent tuberculosis infection FC Von Reyn E Baron In UptoDate 2014 Wolters Kluwer Health 1 16
11. SD Lawn, M Badri, R Wood Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort AIDS 19 2005 2109 2116
12. K Lönnroth, KG Castro, JM Chakaya et al. tuberculosis control and elimination 2010-50: cure, care, and social development Lancet 375 2010 1814 1829
13. C Dye, P Glaziou, K Floyd, M Raviglione Prospects for tuberculosis elimination Annu Rev Public Health 34 2013 271 286
14. D Alland, GE Kalkut, AR Moss et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods New Engl J Med 330 1994 1710 1716
15. PM Small, PC Hopewell, SP Singh et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods New Engl J Med 330 1994 1703 1709
16. MW Borgdorff, D van Soolingen The re-emergence of tuberculosis: what have we learnt from molecular epidemiology? Clin Microbiol Infect 19 2013 889 901
17. JL Gardy, JC Johnston, SJ Ho Sui et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak N Engl J Med 364 2011 730 739
18. R Wood, C Morrow, S Ginsberg et al. Quantification of shared air: a social and environmental determinant of airborne disease transmission PLoS One 9 2014 e106622
19. M Cruciani, M Malena, O Bosco, G Gatti, G Serpelloni The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis Clin Infect Dis 33 2001 1922 1930
20. E Vynnycky, PE Fine The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection Epidemiol Infect 119 1997 183 201
21. D Portevin, S Gagneux, I Comas, D Young Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages PLoS Pathog 7 2011 e1001307
22. BD Robertson, D Altmann, C Barry et al. Detection and treatment of subclinical tuberculosis Tuberculosis (Edinb) 92 2012 447 452
23. SV Capuano 3rd, DA Croix, S Pawar et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection Infect Immun 71 2003 5831 5844
24. PL Lin, A Myers, L Smith et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model Arthritis Rheum 62 2010 340 350
25. PL Lin, CB Ford, MT Coleman et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing Nat Med 20 2014 75 79
26. N Ghesani, A Patrawalla, A Lardizabal, P Salgame, KP Fennelly Increased cellular activity in thoracic lymph nodes in early human latent tuberculosis infection Am J Respir Crit Care Med 189 2014 748 750
27. CE Barry 3rd, HI Boshoff, V Dartois et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies Nat Rev Microbiol 7 2009 845 855
28. H Esmail, CE Barry 3rd, DB Young, RJ Wilkinson The ongoing challenge of latent tuberculosis Philos Trans R Soc Lond B Biol Sci 369 2014 20130437
29. L Ramakrishnan Revisiting the role of the granuloma in tuberculosis Nat Rev Immunol 12 2012 352 366
30. MT Coleman, RY Chen, M Lee et al. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis Sci Transl Med 6 2014 265ra167
31. IM Orme, RT Robinson, AM Cooper The balance between protective and pathogenic immune responses in the TB-infected lung Nat Immunol 16 2015 57 63
32. A Dorhoi, SH Kaufmann Perspectives on host adaptation in response to Mycobacterium tuberculosis: modulation of inflammation Semin Immunol 26 2014 533 542
33. A Cobat, CJ Gallant, L Simkin et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis J Exp Med 206 2009 2583 2591
34. M Matsumiya, I Satti, A Chomka et al. Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model J Infect Dis 211 2015 1499 1509
35. CM Denkinger, K Dheda, M Pai Guidelines on interferon-γ release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 17 2011 806 814
36. NICE Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control 2011 National Institute for Health and Care Excellence London
37. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection MMWR 59 2010 1 25
38. WHO Guidelines on the management of latent tuberculosis infection 2015 World Health Organization Geneva
39. M Pai, CM Denkinger, SV Kik et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection Clin Microbiol Rev 27 2014 3 20
40. K Dheda, M Ruhwald, G Theron, J Peter, WC Yam Point-of-care diagnosis of tuberculosis: past, present and future Respirology 18 2013 217 232
41. K Dheda, R van Zyl Smit, M Badri, M Pai T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings Curr Opin Pulm Med 15 2009 188 200
42. SH Ferebee, FW Mount Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts Am Rev Respir Dis 85 1962 490 510
43. M Sester, G Sotgiu, C Lange et al. Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis Eur Respir J 37 2011 100 111
44. M Farhat, C Greenaway, M Pai, D Menzies False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 10 2006 1192 1204
45. SE Dorman, R Belknap, EA Graviss the tuberculosis Epidemiologic Studies Consortium Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States Am J Respir Crit Care Med 189 2014 77 87
46. S Adams, R Ehrlich, R Baatjies et al. Incidence of occupational latent tuberculosis infection in South African healthcare workers Eur Respir J 45 2015 1364 1373
47. R Diel, R Loddenkemper, A Nienhaus Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis Chest 142 2012 63 75
48. MX Rangaka, KA Wilkinson, JR Glynn et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis Lancet Infect Dis 12 2012 45 55
49. WHO Systematic screening for active tuberculosis: Principles and recommendations 2013 World Health Organization Geneva
50. WHO Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings 2011 World Health Organization Geneva
51. AY Sun, M Pai, H Salje, S Satyanarayana, S Deo, DW Dowdy Modeling the impact of alternative strategies for rapid molecular diagnosis of tuberculosis in Southeast Asia Am J Epidemiol 178 2013 1740 1749
52. MS Khan, O Dar, C Sismanidis, K Shah, P Godfrey-Faussett Improvement of tuberculosis case detection and reduction of discrepancies between men and women by simple sputum-submission instructions: a pragmatic randomised controlled trial Lancet 369 2007 1955 1960
53. JG Peter, G Theron, A Pooran, J Thomas, M Pascoe, K Dheda Comparison of two methods for acquisition of sputum samples for diagnosis of suspected tuberculosis in smear-negative or sputum-scarce people: a randomised controlled trial Lancet Respir Med 1 2013 471 478
54. WHO Same-day diagnosis of tuberculosis by microscopy 2011 World Health Organization Geneva
55. KR Steingart, M Henry, V Ng et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review Lancet Infect Dis 6 2006 570 581
56. A Whitelaw, J Peter, H Sohn et al. Comparative cost and performance of light-emitting diode microscopy in HIV-tuberculosis-co-infected patients Eur Respir J 38 2011 1393 1397
57. RN van Zyl-Smit, A Binder, R Meldau et al. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden PLoS One 6 2011 e28815
58. M Cruciani, C Scarparo, M Malena, O Bosco, G Serpelloni, C Mengoli Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria J Clin Microbiol 42 2004 2321 2325
59. WHO Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrugresistant tuberculosis 2011 World Health Organization Geneva
60. WHO Xpert MTB/RIF implementation manual 2014 World Health Organization Geneva
61. WHO The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs 2013 World Health Organization Geneva
62. M Barnard, NC Gey van Pittius, PD van Helden, M Bosman, G Coetzee, RM Warren The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay J Clin Microbiol 50 2012 3712 3716
63. VB Patel, G Theron, L Lenders et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous meningitis in a high burden setting: a prospective study PLoS Med 10 2013 e1001536
64. S Pandie, JG Peter, ZS Kerbelker et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon-γ in a high burden setting: a prospective study BMC Med 12 2014 101
65. KR Steingart, I Schiller, DJ Horne, M Pai, CC Boehme, N Dendukuri Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults Cochrane Database Syst Rev 1 2014 CD009593
66. G Theron, J Peter, R van Zyl-Smit et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting Am J Respir Crit Care Med 184 2011 132 140
67. G Theron, L Zijenah, D Chanda the TB-NEAT team Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial Lancet 383 2014 424 435
68. I Langley, HH Lin, S Egwaga et al. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach Lancet Glob Health 2 2014 e581 e591
69. SO Friedrich, A Rachow, E Saathoff the Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA) Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment Lancet Respir Med 1 2013 462 470
70. HS Cox, S Mbhele, N Mohess et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial PLoS Med 11 2014 e1001760
71. GJ Churchyard, WS Stevens, LD Mametja et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF Lancet Glob Health 3 2015 e450 e457
72. WHO Rapid Implementation of the Xpert MTB/RIF diagnostic test: Technical and operational 'How-to' Practical considerations 2011 World Health Organization Geneva
73. G Theron, J Peter, M Richardson et al. The diagnostic accuracy of the GenoType®MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs Cochrane Database Syst Rev 10 2014 CD010705
74. CU Köser, JM Bryant, J Becq et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis N Engl J Med 369 2013 290 292
75. JG Peter, G Theron, R van Zyl-Smit et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients Eur Respir J 40 2012 1211 1220
76. SD Lawn, K Dheda, AD Kerkhoff et al. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies BMC Infect Dis 13 2013 407
77. J Minion, E Leung, E Talbot, K Dheda, M Pai, D Menzies Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis Eur Respir J 38 2011 1398 1405
78. BL Young, Z Mlamla, PP Gqamana et al. The identification of tuberculosis biomarkers in human urine samples Eur Respir J 43 2014 1719 1729
79. ST Chambers, A Scott-Thomas, M Epton Developments in novel breath tests for bacterial and fungal pulmonary infection Curr Opin Pulm Med 18 2012 228 232
80. ST Anderson, M Kaforou, AJ Brent the ILULU Consortium the KIDS TB Study Group Diagnosis of childhood tuberculosis and host RNA expression in Africa N Engl J Med 370 2014 1712 1723
81. MP Berry, CM Graham, FW McNab et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis Nature 466 2010 973 977
82. KR Steingart, LL Flores, N Dendukuri et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis PLoS Med 8 2011 e1001062
83. LL Flores, KR Steingart, N Dendukuri et al. Systematic review and meta-analysis of antigen detection tests for the diagnosis of tuberculosis Clin Vaccine Immunol 18 2011 1616 1627
84. ME Kruk, NR Schwalbe, CA Aguiar Timing of default from tuberculosis treatment: a systematic review Trop Med Int Health 13 2008 703 712
85. R Steffen, D Menzies, O Oxlade et al. Patients' costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil PLoS One 5 2010 e14014
86. TR Frieden, JA Sbarbaro Promoting adherence to treatment for tuberculosis: the importance of direct observation Bull World Health Organ 85 2007 407 409
87. JG Pasipanodya, T Gumbo A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients Clin Infect Dis 57 2013 21 31
88. WHO THE STOP TB STRATEGY, Building on and enhancing DOTS to meet the TB-related Millennium Development Goals 2006 World Health Organization Geneva http://whqlibdoc.who.int/hq/2006/WHO-HTM-STB-2006.368-eng.pdf?ua=1 (accessed July 1, 2015).
89. WR Mac Kenzie, CM Heilig, L Bozeman et al. Geographic differences in time to culture conversion in liquid media: tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa PLoS One 6 2011 e18358
90. M Weiner, C Peloquin, W Burman et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations Antimicrob Agents Chemother 54 2010 4192 4200
91. E Chigutsa, ME Visser, EC Swart et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications Antimicrob Agents Chemother 55 2011 4122 4127
92. JJ Saukkonen, DL Cohn, RM Jasmer the ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee An official ATS statement: hepatotoxicity of antituberculosis therapy Am J Respir Crit Care Med 174 2006 935 952
93. SK Sharma, R Singla, P Sarda et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity Clin Infect Dis 50 2010 833 839
94. K Prasad, MB Singh Corticosteroids for managing tuberculous meningitis Cochrane Database Syst Rev 1 2008 CD002244
95. JA Critchley, F Young, L Orton, P Garner Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis Lancet Infect Dis 13 2013 223 237
96. BM Mayosi, M Ntsekhe, J Bosch the IMPI Trial Investigators Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis N Engl J Med 371 2014 1121 1130
97. AC Crampin, JN Mwaungulu, FD Mwaungulu et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi AIDS 24 2010 417 426
98. H McIlleron, G Meintjes, WJ Burman, G Maartens Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome J Infect Dis 196 suppl 1 2007 S63 S75
99. CDC Tuberculosis National Center for HIV/AIDS VH, STD, and TB Prevention, Division of tuberculosis Elimination, Managing Drug Interactions in the Treatment of HIV-Related tuberculosis National http://www.cdc.gov/tb/publications/guidelines/tb-hiv-drugs/pdf/tbhiv.pdf 2013 (accessed July 1, 2015).
100. M Müller, S Wandel, R Colebunders, S Attia, H Furrer, M Egger the IeDEA Southern and Central Africa Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis Lancet Infect Dis 10 2010 251 261
101. OA Uthman, C Okwundu, K Gbenga et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis Ann Intern Med 163 2015 32 39
102. V Yuzbasiyan-Gurkan, V Johnson, GJ Brewer Diagnosis and characterization of presymptomatic patients with Wilson's disease and the use of molecular genetics to aid in the diagnosis J Lab Clin Med 118 1991 458 465
103. R Tadokera, G Meintjes, KH Skolimowska et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome Eur Respir J 37 2011 1248 1259
104. BB Andrade, A Singh, G Narendran et al. Mycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome PLoS Pathog 10 2014 e1004433
105. DL Barber, BB Andrade, I Sereti, A Sher Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none Nat Rev Microbiol 10 2012 150 156
106. G Meintjes, RJ Wilkinson, C Morroni et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome AIDS 24 2010 2381 2390
107. American Thoracic Society CDC Infectious Diseases Society of America Treatment of tuberculosis 2003 US Department of Health and Human Services Atlanta
108. DA Mitchison, AJ Nunn Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis Am Rev Respir Dis 133 1986 423 430
109. Hong Kong Chest Service/British Medical Research Council Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis Am Rev Respir Dis 136 1987 1339 1342
110. WHO WHO updated references on management of drug-resistant tuberculosis: guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update 2011 World Health Organization Geneva
111. C Lange, I Abubakar, JW Alffenaar et al. Management of patients with multidrugresistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement 2014 ERS Publications Lausanne
112. G Sotgiu, R Centis, L D'Ambrosio et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis Eur Respir J 40 2012 1430 1442
113. KC Chang, WW Yew, CM Tam, CC Leung WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis Antimicrob Agents Chemother 57 2013 4097 4104
114. WHO The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance 2013 World Health Organization Geneva
115. WHO The use of delaminid in the treatment of mutlidrug-resistant tuberculosis: Interim policy guidance 2014 World Health Organization Geneva
116. B Müller, S Borrell, G Rose, S Gagneux The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis Trends Genet 29 2013 160 169
117. KR Jacobson, DB Tierney, CY Jeon, CD Mitnick, MB Murray Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis Clin Infect Dis 51 2010 6 14
118. B Muller, EM Streicher, KG Hoek et al. inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa? Int J Tuberc Lung Dis 15 2011 344 351
119. WHO The role of surgery in the treatment of pulmonary TB and multidrug- and extensively drug-resistant TB 2014 Regional Office for Europe, World Health Organization Copenhagen
120. RY Chen, LE Dodd, M Lee et al. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis Sci Transl Med 6 2014 265ra166
121. 18F-FDG PET and PET/CT Curr Opin Pulm Med 20 2014 287 293
122. M Loveday, K Wallengren, J Brust et al. Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa Int J Tuberc Lung Dis 19 2015 163 171
123. K Dheda, GB Migliori The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? Lancet 379 2012 773 775
124. N Heinrich, R Dawson, J du Bois the Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) the Pan African Consortium for the Evaluation of Antituberculosis Antibiotics PanACEA Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients J Antimicrob Chemother 70 2015 1558 1566
125. AH Diacon, RF Patientia, A Venter et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears Antimicrob Agents Chemother 51 2007 2994 2996
126. MJ Boeree, AH Diacon, R Dawson the PanACEA Consortium A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis Am J Respir Crit Care Med 191 2015 1058 1065
127. SE Dorman, RM Savic, S Goldberg the tuberculosis Trials Consortium Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial Am J Respir Crit Care Med 191 2015 333 343
128. E Chigutsa, JG Pasipanodya, ME Visser et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis Antimicrob Agents Chemother 59 2015 38 45
129. R Dawson, AH Diacon, D Everitt et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis Lancet 385 2015 1738 1747
130. AH Diacon, R Dawson, F von Groote-Bidlingmaier et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline Am J Respir Crit Care Med 191 2015 943 953
131. A Jindani, TS Harrison, AJ Nunn the RIFAQUIN Trial Team High-dose rifapentine with moxifloxacin for pulmonary tuberculosis N Engl J Med 371 2014 1599 1608
132. CS Merle, K Fielding, OB Sow the OFLOTUB/Gatifloxacin for tuberculosis Project A four-month gatifloxacin-containing regimen for treating tuberculosis N Engl J Med 371 2014 1588 1598
133. SH Gillespie, AM Crook, TD McHugh the REMoxTB Consortium Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis N Engl J Med 371 2014 1577 1587
134. R Rustomjee, C Lienhardt, T Kanyok et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis Int J Tuberc Lung Dis 12 2008 128 138
135. SK Katiyar, S Bihari, S Prakash, M Mamtani, H Kulkarni A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis Int J Tuberc Lung Dis 12 2008 139 145
136. A Van Deun, AK Maug, MA Salim et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis Am J Respir Crit Care Med 182 2010 684 692
137. AH Diacon, A Pym, MP Grobusch the TMC207-C208 Study Group Multidrug-resistant tuberculosis and culture conversion with bedaquiline N Engl J Med 371 2014 723 732
138. MT Gler, V Skripconoka, E Sanchez-Garavito et al. Delamanid for multidrug-resistant pulmonary tuberculosis N Engl J Med 366 2012 2151 2160
139. M Lee, J Lee, MW Carroll et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis N Engl J Med 367 2012 1508 1518
140. N Field, MS Lim, J Murray, RJ Dowdeswell, JR Glynn, P Sonnenberg Timing, rates, and causes of death in a large South African tuberculosis programme BMC Infect Dis 14 2014 3858
141. A Odone, S Amadasi, RG White, T Cohen, AD Grant, RM Houben The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis PLoS One 9 2014 e112017
142. K Dheda, H Booth, JF Huggett, MA Johnson, A Zumla, GA Rook Lung remodeling in pulmonary tuberculosis J Infect Dis 192 2005 1201 1209
143. L Moodley, J Pillay, K Dheda Aspergilloma and the surgeon J Thorac Dis 6 2014 202 209
144. G Cucchetto, A Cazzadori, M Conti, GL Cascio, P Braggio, E Concia Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series Infection 43 2015 277 286
145. BW Allwood, L Myer, ED Bateman A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults Respiration 86 2013 76 85
146. CW Ong, PT Elkington, JS Friedland tuberculosis, pulmonary cavitation, and matrix metalloproteinases Am J Respir Crit Care Med 190 2014 9 18
147. WHO Global strategy and targets for tuberculosis prevention, care and control after 2015 2013 World Health Organization Geneva http://apps.who.int/gb/ebwha/pdf-files/EB134/B134-12-en.pdf (accessed July 1, 2015).
148. HR Stagg, D Zenner, RJ Harris, L Muñoz, MC Lipman, I Abubakar Treatment of latent tuberculosis infection: a network meta-analysis Ann Intern Med 161 2014 419 428
149. C Akolo, I Adetifa, S Shepperd, J Volmink Treatment of latent tuberculosis infection in HIV infected persons Cochrane Database Syst Rev 1 2010 CD000171
150. AD Kerkhoff, A Gupta, T Samandari, SD Lawn The proportions of people living with HIV in low and middle-income countries who test tuberculin skin test positive using either a 5 mm or a 10 mm cut-off: a systematic review BMC Infect Dis 13 2013 307
151. R Wood, G Maartens, CJ Lombard Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis J Acquir Immune Defic Syndr 23 2000 75 80
152. RM Houben, T Sumner, AD Grant, RG White Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings Proc Natl Acad Sci USA 111 2014 5325 5330
153. WHO Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with hiv in resource-constrained settings 2011 World Health Organization Geneva http://whqlibdoc.who.int/publications/2011/9789241500708-eng.pdf?ua=1 (accessed July 1, 2015).
154. T Samandari, TB Agizew, S Nyirenda et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial Lancet 377 2011 1588 1598
155. MX Rangaka, RJ Wilkinson, JR Glynn et al. Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic Clin Infect Dis 55 2012 1698 1706
156. MX Rangaka, RJ Wilkinson, A Boulle et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial Lancet 384 2014 682 690
157. TG Evans, MJ Brennan, L Barker, J Thole Preventive vaccines for tuberculosis Vaccine 31 suppl 2 2013 B223 B226
158. WHO An international roadmap for tuberculosis research 2011 World Health Organization Geneva
159. K Dheda, A Zumla, P Onyebujoh Research priorities in tuberculosis A Zumla S Schaaf A treatise of tuberculosis 2008 Elsevier London